Eli Lilly is required by law to create a package insert that describes in detail everything that patients need to know about Cymbalta before taking it.
There is a section within this package insert called, "5.6 Discontinuation of Treatment with Cymbalta." It describes the "known" problems that people have when stopping the use of this drug:
During marketing of other SSRIs and SNRIs (serotonin and norepinephrine reuptake inhibitors), there have been spontaneous reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: dysphoric mood, irritability, agitation, dizziness, sensory disturbances (e.g., paresthesias such as electric shock sensations), anxiety, confusion, headache, lethargy, emotional lability, insomnia, hypomania, tinnitus, and seizures. Although these events are generally self-limiting, some have been reported to be severe.
Patients should be monitored for these symptoms when discontinuing treatment with Cymbalta. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate [see Dosage and Administration (2.4)].
Eli Lilly fails to mention "withdrawal" as a symptom of discontinuing Cymbalta. Withdrawal symptoms are defined as abnormal physical or psychological features that follow the abrupt discontinuation of a drug that has the capability of producing physical dependence. Withdrawal is a term referring to the feelings of discomfort, distress, and intense craving for a substance that occur when use of the substance is stopped. These physical symptoms occur because the body had become metabolically adapted to the substance. The withdrawal symptoms of Cymbalta can range from mild discomfort resembling the flu to severe withdrawal that can actually be life threatening.
Our firms are investigating problems with symptoms from the discontinuation of use of Cymbalta. Please use the form below to tell us about your situation. We will contact you by phone as soon as possible.
Your confidentiality matters. No information, including phone numbers and email addresses will be exchanged, shared or sold to a third party. Any communications to our firm via contact forms, email, phone or U.S. mail, will be treated confidentially. Submissions are made for the purpose of evaluating whether or not our law firm will accept your case and represent you. However, all information contained in your submission will be held confidential. By evaluating your submission we make no representation or agreement to represent you in connection with your claim. Thank you.